Jersey Shore Ready ...
Health Care: Drugs
AMAG Pharmaceuticals Inc. (AMAG: NASDAQ)
$22.25 0.31 | 1.41%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 22.25 |
| 52 Week High | 25.67 |
| 52 Week Low | 13.38 |
| Avg. Daily Vol. (Mil) | 0.14 |
| Beta (3 year) | 0.27 |
| Share Related Items | |
| Mkt Cap (Mil) | 480.04 |
| Shares Out (Mil) | 21.57 |
| Float (Mil) | 12.53 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 8.40 |
| Current Ratio | 9.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.47 |
| Price/Book | 2.80 |
| Price/Cash Flow | -206.00 |
| Per Share Data | |
| Earnings | -0.39 |
| Sales | 4.07 |
| Book Value | 7.94 |
| Cash Flow | -0.11 |
| Business Summary | |
|---|---|
| AMAG Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of Feraheme (ferumoxytol) Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA. | |
| General Information | |
| 100 Hayden Avenue
Lexington, MA 02421 |
|
| www.amagpharma.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 129 | |
| CEO: William K. Heiden | |
| Short Interest | |
| Current Month (Mil) | 0.88 |
| Previous Month (Mil) | 0.76 |
| Short Interest Ratio (Days) | 5.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -3.30 |
| Return on Investments | -4.80 |
| Profitability | |
| Gross Margin | 90.20 |
| EBIT Margin | -10.30 |
| Profit Margin | -9.40 |
Portfolios with AMAG
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- UserPelican Watch
- UserPART 1 JPMorgan 28th Annual...
- UserPART 1 JPMorgan 27th Annual...
- Userileana
- UserShawen Portfolio 1
- Userfiallo Portfolio 1
Latest AMAG Headlines from TheStreet
- Ferumoxytol Treatment Produced Significant Hemoglobin Increases In Adult Iron Deficiency Anemia Patients With Gastrointestinal Disease Who Had Failed Or Could Not Tolerate Oral Iron Therapy 05.21.13 | 08:05 am
- 2013 FDA Drug Approval Calendar 05.21.13 | 07:05 am
- Ferumoxytol Results In Significant Hemoglobin Increases In Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed Or Could Not Tolerate Oral Iron Therapy 05.06.13 | 08:05 am
- Kudos To Keryx, But Can Zerenex Zing? 01.28.13 | 10:01 am
- 5 Stocks Ready to Break Out 01.18.13 | 12:01 pm
- 3 Unusual-Volume Stocks Moving Higher 11.01.12 | 02:11 pm
- AMAG Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript) 09.10.12 | 03:09 pm
- AMAG Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript 07.26.12 | 11:07 am
- AMAG Pharmaceuticals' CEO Presents IDA-301 Data (Transcript) 07.20.12 | 01:07 am
- 8 Stocks Rising on Huge Volume 04.20.12 | 01:04 pm
Press Releases for AMAG
- AMAG Pharmaceuticals Announces Positive Preliminary Results From An Extension Study Evaluating The Safety And Efficacy Of Repeat Dosing With Ferumoxytol In Patients With Persistent Or Recurring Iron Deficiency Anemia, Regardless Of The Underlying Cause - Business Wire 03.15.13 | 06:03 am
- AMAG Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Feraheme Label Expansion To Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron - Business Wire 03.06.13 | 08:03 am
- AMAG Announces Fourth Quarter And Year End 2012 Financial Results - Business Wire 03.01.13 | 08:03 am
- AMAG Pharmaceuticals, Inc. To Present At Upcoming Healthcare Conferences - Business Wire 02.21.13 | 04:02 pm
- Branham Law, LLP Investigates AMAG Pharmaceuticals On Behalf Of Stockholders - Business Wire 02.11.13 | 04:02 pm
- AMAG Pharmaceuticals, Inc. To Present At The Leerink Swann Global Healthcare Conference - Business Wire 02.07.13 | 05:02 pm
- AMAG Pharmaceuticals Provides Business Update Announces Preliminary 2012 Financial Results And 2013 Financial Guidance - Business Wire 01.06.13 | 07:01 am
- AMAG Pharmaceuticals Appoints Greg Madison As Chief Commercial Officer - Business Wire 01.02.13 | 08:01 am
- AMAG Pharmaceuticals, Inc. To Present At The 31st Annual J.P. Morgan Healthcare Conference - Business Wire 12.26.12 | 08:12 am
- AMAG Pharmaceuticals Announces FDA Submission Of A Supplemental New Drug Application For Feraheme - Business Wire 12.24.12 | 08:12 am
Partner Headlines for AMAG
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.10.12 | 09:10 am
- AMAG Beats Expectations - Analyst Blog - Zacks 08.01.12 | 09:08 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 07.27.12 | 09:07 am
- Akamai Tech REITERATED at Hold and 2 Must-See Reiterated Ratings - Wall St. Cheat Sheet 07.26.12 | 02:07 am
- AMAG Beats Riding on Feraheme Sales - Analyst Blog - Zacks 05.02.12 | 10:05 am
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- AMAG Pharmaceuticals Reports Mixed Q4 Results - Benzinga 03.05.12 | 04:03 pm
- Israel Englander's Stock Picks With Insider Purchases - Seeking Alpha 01.18.12 | 09:01 am
- 17 Breakout Stocks Boosted By Insiders - Seeking Alpha 12.30.11 | 04:12 pm
- McNicoll Lewis & Vlak Raises PT on AMAG Pharmaceuticals to $23 - Benzinga 12.12.11 | 01:12 pm
